Stempoint Capital LP holds a diversified book of 73 reported positions worth $577.9M as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). This quarter First Tracks Biotherapeutics first appears in 13F filings (one of 2 new listings in the book), a listing rather than a purchase; they opened Kiniksa Pharmaceuticals Inte and trimmed Abivax Sa-ADR. Their largest long position is Tango Therapeutics Inc at 7% of the reported non-option book. They also disclosed $748K in put options (a bearish bet) and $1.9M in call options (bullish), shown separately below and excluded from the non-option book. Cloning the disclosed picks since 2024 would be +24% (+8.7%/yr). That is a simulation of the disclosed long book, not audited returns.
The reported book (valued from quarter-end) returned +48.3%, a 24.0-point gap that is the cost of the ~45-day 13F disclosure lag a real follower can't avoid.
Growth of $10,000 cloning Stempoint Capital LP's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~45 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
99% mapped to company sectors
+1 sector below the cut, under 0.5% together
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as Stempoint Capital LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Patient Square Capital LP | 11 / 73 | $455.8M |
| Avidity Partners Management LP | 7 / 73 | $415.9M |
| Commodore Capital LP | 20 / 73 | $1.1B |
| TCG Crossover Management, LLC | 20 / 73 | $2.7B |
| Boxer Capital Management, LLC | 19 / 73 | $849.8M |
| First Turn Management, LLC | 16 / 73 | $568.2M |
| Cormorant Asset Management, LP | 24 / 73 | $1.2B |
| Spruce Street Capital LP | 13 / 73 | $293.2M |
Ranked by the share of each fund's own book sitting in the names it shares with Stempoint Capital LP: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each position's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Tango Therapeutics Inc COM | $38.2M | 1.22M | 6.6% | ▲New New position | |
| 2 | Abivax Sa SPONSORED ADS | $37.8M | 283.7K | 6.5% | ▼−28% Reduced · −108K sh | |
| 3 | Revolution Medicines Inc COM | $30.0M | 159.9K | 5.2% | ▲+158% Added · +98K sh | |
| 4 | Erasca Inc COM | $28.7M | 1.57M | 5.0% | ▲New New position | |
| 5 | Tyra Biosciences Inc COM | $20.2M | 632.8K | 3.5% | ▲New New position | |
| 6 | Dianthus Therapeutics Inc COM | $19.6M | 200.9K | 3.4% | ▲+153% Added · +122K sh | |
| 7 | Enliven Therapeutics Inc COM | $17.6M | 346.9K | 3.0% | ▲New New position | |
| 8 | Mineralys Therapeutics Inc COM | $16.3M | 602.7K | 2.8% | ▲+108% Added · +313K sh | |
| 9 | Biohaven Ltd COM | $15.8M | 1.06M | 2.7% | ▲New New position | |
| 10 | Surrozen Inc COM NEW | $13.8M | 602.8K | 2.4% | ▼−2.7% Reduced · −17K sh | |
| 11 | Kiniksa Pharmaceuticals Intl ORD SHS CL A | $13.4M | 209.2K | 2.3% | ▲New New position | |
| 12 | Scholar Rock Hldg Corp COM | $13.2M | 239.1K | 2.3% | ▼−73% Reduced · −648K sh | |
| 13 | Alkermes PLC SHS | $13.0M | 248.0K | 2.2% | ▲New New position | |
| 14 | First Tracks Biotherapeutics ORD SHS | $12.5M | 622.7K | 2.2% | →Listed Newly reportable | |
| 15 | Praxis Precision Medicines I COM NEW | $12.5M | 37.2K | 2.2% | ▲+77% Added · +16K sh | |
| 16 | Roivant Sciences Ltd SHS | $12.3M | 348.4K | 2.1% | ▼−64% Reduced · −618K sh | |
| 17 | Bioage Labs Inc COM | $11.4M | 464.2K | 2.0% | ▲New New position | |
| 18 | CG Oncology Inc COM | $11.3M | 159.3K | 2.0% | ▲New New position | |
| 19 | Oruka Therapeutics Inc COM | $11.1M | 116.5K | 1.9% | ▲New New position | |
| 20 | Immunovant Inc COM | $10.7M | 276.5K | 1.8% | ▼−57% Reduced · −368K sh | |
| 21 | Celcuity Inc COM | $10.3M | 98.2K | 1.8% | ▼−17% Reduced · −20K sh | |
| 22 | Relmada Therapeutics Inc COM | $10.1M | 1.46M | 1.7% | ▲New New position | |
| 23 | Climb Bio Inc COM | $9.7M | 742.7K | 1.7% | ▲New New position | |
| 24 | Spyre Therapeutics Inc COM NEW | $9.5M | 106.9K | 1.6% | ▲+230% Added · +75K sh | |
| 25 | Zura Bio Ltd CLASS A ORD SHS | $8.1M | 1.37M | 1.4% | ▲New New position | |
| 26 | Inflarx NV COM | $7.2M | 3.23M | 1.3% | ▲New New position | |
| 27 | Amylyx Pharmaceuticals Inc COM | $6.9M | 384.3K | 1.2% | ▼−32% Reduced · −181K sh | |
| 28 | Celldex Therapeutics Inc New COM NEW | $6.6M | 178.4K | 1.1% | ▲New New position | |
| 29 | Ovid Therapeutics Inc COM | $6.5M | 2.42M | 1.1% | ▲New New position | |
| 30 | Equillium Inc COM | $6.5M | 2.02M | 1.1% | ▲New New position | |
| 31 | Definium Therapeutics Inc COM SHS | $6.5M | 137.1K | 1.1% | ▲New New position | |
| 32 | Cytokinetics Inc COM NEW | $6.4M | 75.6K | 1.1% | ▼−49% Reduced · −71K sh | |
| 33 | Damora Therapeutics Inc COM NEW | $5.6M | 216.2K | 1.0% | ▲New New position | |
| 34 | Inventiva Sa ADS | $5.4M | 1.43M | 0.9% | ▲+205% Added · +959K sh | |
| 35 | Century Therapeutics Inc COM | $5.3M | 2.15M | 0.9% | ▲New New position | |
| 36 | Aura Biosciences Inc COM | $5.1M | 714.3K | 0.9% | ▲New New position | |
| 37 | Eyepoint Inc COM NEW | $4.8M | 338.5K | 0.8% | ▼−4.3% Reduced · −15K sh | |
| 38 | Assembly Biosciences Inc COM NEW | $4.7M | 170.4K | 0.8% | ▲+8.7% Added · +14K sh | |
| 39 | Whitehawk Therapeutics Inc COM | $4.7M | 1.02M | 0.8% | ▼−30% Reduced · −438K sh | |
| 40 | Xenon Pharmaceuticals Inc COM | $4.6M | 76.1K | 0.8% | ▼−78% Reduced · −273K sh | |
| 41 | Uniqure NV SHS | $4.1M | 88.1K | 0.7% | ▲+103% Added · +45K sh | |
| 42 | Compass Pathways PLC SPONSORED ADS | $4.0M | 284.8K | 0.7% | ▲New New position | |
| 43 | Avalyn Pharmaceuticals Inc COM SHS | $3.9M | 118.0K | 0.7% | →Listed Newly reportable | |
| 44 | Maplight Therapeutics Inc COM | $3.8M | 106.9K | 0.7% | ▲+6.9% Added · +7K sh | |
| 45 | Alumis Inc COM | $3.8M | 135.7K | 0.7% | ▲New New position | |
| 46 | Axsome Therapeutics Inc. COM | $3.8M | 15.4K | 0.7% | ▲New New position | |
| 47 | Monte Rosa Therapeutics Inc COM | $3.7M | 153.5K | 0.6% | ▲+149% Added · +92K sh | |
| 48 | Acadia Pharmaceuticals Inc COM | $3.6M | 143.2K | 0.6% | ▲New New position | |
| 49 | Solid Biosciences Inc COM NEW | $3.6M | 358.8K | 0.6% | ▲New New position | |
| 50 | Personalis Inc COM | $3.3M | 247.8K | 0.6% | ▲New New position |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1952142/holdings"
Use Arkolith to show STEMPOINT CAPITAL LP's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | PERSONALIS INCPSNL | $811K | 470K |
| CALL · bullish | BIOHAVEN LTDBHVN | $525K | 500K |
| PUT · bearish | SS SPDR S&P BIOTECH ETFXBI | $400K | 250K |
| CALL · bullish | ASTRAZENECA PLCAZN | $180K | 25K |
| CALL · bullish | SS SPDR S&P BIOTECH ETFXBI | $178K | 400K |
| CALL · bullish | TANGO THERAPEUTICS INCTNGX | $175K | 100K |
| PUT · bearish | REVOLUTION MEDICINES INCRVMD | $128K | 30K |
| PUT · bearish | ERASCA INCERAS | $90K | 200K |
| PUT · bearish | ARK GENOMIC REVOLUTION ETFARKG | $75K | 100K |
| PUT · bearish | ROIVANT SCIENCES LTDROIV | $40K | 100K |
| PUT · bearish | AMGEN INCAMGN | $15K | 15K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the non-option book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
| Quarter | As of | Filed | Lag | Positions | Value | Form |
|---|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 14, 2026 | 45d | 85 | $580.5M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 18, 2026 | 48d | 84 | $522.3M | 13F-HR/A |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 48d | 78 | $583.2M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 45d | 90 | $499.1M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 45d | 54 | $311.6M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 45d | 62 | $313.7M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 45d | 58 | $400.6M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 13, 2024 | 44d | 58 | $334.0M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 13, 2024 | 44d | 44 | $340.3M | 13F-HR/A |
| Q1 2024 | Mar 31, 2024 | Aug 9, 2024 | 131d | 63 | $378.3M | 13F-HR/A |
| Q4 2023 | Dec 31, 2023 | Feb 13, 2024 | 44d | 70 | $374.8M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. Book totals and portfolio weights cover reported non-option positions, which can include notes and warrants. Disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.